Cord blood antibodies following BBIBP-CorV (Sinopharm) vaccination during pregnancy
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd..
OBJECTIVE: This study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy.
METHOD: The women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered.
RESULT: A total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p = .025). The same result was demonstrated in infants born to these mothers (p = .019).
CONCLUSION: There was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Immunity, inflammation and disease - 11(2023), 6 vom: 20. Juni, Seite e874 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hantoushzadeh, Sedigheh [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 30.06.2023 Date Revised 02.07.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/iid3.874 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35883547X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35883547X | ||
003 | DE-627 | ||
005 | 20231226075606.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/iid3.874 |2 doi | |
028 | 5 | 2 | |a pubmed24n1196.xml |
035 | |a (DE-627)NLM35883547X | ||
035 | |a (NLM)37382259 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hantoushzadeh, Sedigheh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cord blood antibodies following BBIBP-CorV (Sinopharm) vaccination during pregnancy |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.06.2023 | ||
500 | |a Date Revised 02.07.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. | ||
520 | |a OBJECTIVE: This study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy | ||
520 | |a METHOD: The women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered | ||
520 | |a RESULT: A total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p = .025). The same result was demonstrated in infants born to these mothers (p = .019) | ||
520 | |a CONCLUSION: There was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Iran | |
650 | 4 | |a Sinopharm | |
650 | 4 | |a antibody | |
650 | 4 | |a cord blood | |
650 | 4 | |a maternal mortality | |
650 | 4 | |a pregnancy | |
650 | 4 | |a vaccine | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a BIBP COVID-19 vaccine |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
700 | 1 | |a Eshraghi, Nasim |e verfasserin |4 aut | |
700 | 1 | |a Younesi, Sarang |e verfasserin |4 aut | |
700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
700 | 1 | |a Hasheminejad, Mohammad Mehdi |e verfasserin |4 aut | |
700 | 1 | |a Rashidian, Pegah |e verfasserin |4 aut | |
700 | 1 | |a Shirdel, Saeedeh |e verfasserin |4 aut | |
700 | 1 | |a Asadi, Fatemeh |e verfasserin |4 aut | |
700 | 1 | |a Ghaemi, Marjan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Immunity, inflammation and disease |d 2013 |g 11(2023), 6 vom: 20. Juni, Seite e874 |w (DE-627)NLM243574827 |x 2050-4527 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2023 |g number:6 |g day:20 |g month:06 |g pages:e874 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/iid3.874 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2023 |e 6 |b 20 |c 06 |h e874 |